{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000087","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.583146+00:00","generated_at":"2026-06-13T08:45:13.435616+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CB-010 Phase 1 data: 94% ORR, 69% CR in r/r B-NHL; 44% CR ≥6 months; cash ~$292.5M","bullets":["CB-010 achieved 94% ORR (15/16) and 69% CR (11/16) in r/r B-NHL patients in ANTLER Phase 1 dose escalation.","44% of patients (7/16) had CR at ≥6 months; longest CR maintained at 24 months.","LBCL subgroup (N=10): 90% ORR, 70% CR, 50% CR at ≥6 months; longest CR 18 months.","CB-010 generally well tolerated; no Grade 3+ CRS or GvHD; common Grade 3+ events: thrombocytopenia (69%), neutropenia (56%).","Preliminary cash, cash equivalents & marketable securities ~$292.5M as of June 30, 2023; enrolling 2L LBCL in dose expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000087","json":"https://secwatch.observer/filing/0001619856-23-000087.json","markdown":"https://secwatch.observer/filing/0001619856-23-000087.md","text":"https://secwatch.observer/filing/0001619856-23-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000087/0001619856-23-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000087/crbu-20230713.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:45:13.435616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e86f0af55f8a9075b6b562f6d22e72458162fd3c","claim":"Caribou Biosciences, Inc. reported preliminary financial results for the three and six months ended June 30, 2023.","evidence_excerpt":"Preliminary unaudited cash, cash equivalents, and marketable securities as of June 30, 2023 Caribou Biosciences, Inc. (the “Company”) is providing certain preliminary financial results. On a preliminary unaudited basis, the Company expects its cash, cash equivalents, and marketable securities as of June 30, 2023 to be approximately $292.5 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000087/0001619856-23-000087-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}